IRIS
OTTONE, TIZIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.421
EU - Europa 2.573
AS - Asia 2.372
SA - Sud America 389
Continente sconosciuto - Info sul continente non disponibili 384
AF - Africa 31
OC - Oceania 6
Totale 15.176
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.329
IT - Italia 1.146
SG - Singapore 984
CN - Cina 340
BR - Brasile 317
RU - Federazione Russa 274
HK - Hong Kong 244
VN - Vietnam 195
FR - Francia 193
PL - Polonia 193
KR - Corea 178
IE - Irlanda 164
BD - Bangladesh 157
DE - Germania 149
GB - Regno Unito 108
NL - Olanda 82
JP - Giappone 73
UA - Ucraina 65
IN - India 59
FI - Finlandia 54
CA - Canada 50
SE - Svezia 38
AT - Austria 24
ES - Italia 23
ID - Indonesia 23
AR - Argentina 22
MX - Messico 19
CO - Colombia 15
IR - Iran 12
TR - Turchia 12
ZA - Sudafrica 11
IQ - Iraq 10
MY - Malesia 10
BE - Belgio 9
PH - Filippine 9
VE - Venezuela 9
CL - Cile 8
EC - Ecuador 8
PK - Pakistan 8
KZ - Kazakistan 7
LT - Lituania 7
TH - Thailandia 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
AU - Australia 5
GR - Grecia 5
HR - Croazia 5
JM - Giamaica 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
EU - Europa 4
JO - Giordania 4
LU - Lussemburgo 4
PT - Portogallo 4
SA - Arabia Saudita 4
BO - Bolivia 3
CZ - Repubblica Ceca 3
EG - Egitto 3
HU - Ungheria 3
IL - Israele 3
KE - Kenya 3
NG - Nigeria 3
PS - Palestinian Territory 3
SN - Senegal 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CY - Cipro 2
DZ - Algeria 2
GE - Georgia 2
HN - Honduras 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
DK - Danimarca 1
ET - Etiopia 1
GT - Guatemala 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
Totale 14.794
Salva come PNG Salva come JPEG
Città #
Wilmington 1.856
Houston 1.778
Woodbridge 1.452
Singapore 629
Fairfield 355
Ashburn 347
Chandler 341
Dallas 328
San Jose 284
Hong Kong 240
Rome 231
Council Bluffs 171
Kraków 171
Seattle 156
Cambridge 153
Dublin 145
Ann Arbor 142
Beijing 135
New York 129
Medford 101
Milan 93
Santa Clara 84
Dearborn 77
Los Angeles 75
Ho Chi Minh City 74
The Dalles 67
Tokyo 64
Buffalo 53
Lawrence 50
Moscow 48
Lauterbourg 44
Jacksonville 40
Hanoi 39
São Paulo 34
Engelhard 28
Frankfurt am Main 27
Helsinki 27
North Bergen 25
Perugia 24
London 23
Boardman 22
San Diego 22
Munich 21
Zhengzhou 21
Chennai 20
Warsaw 19
Bologna 18
Phoenix 18
Toronto 18
Creede 17
Denver 17
Jakarta 17
Seoul 16
Chicago 15
Florence 15
Naples 15
Atlanta 14
Bari 14
Menlo Park 14
Montreal 14
Nuremberg 14
Orem 14
San Francisco 14
Brooklyn 13
Center 13
Hackensack 13
Palermo 13
Amsterdam 12
Stockholm 12
Columbus 11
Redondo Beach 11
Turin 11
Rio de Janeiro 10
Vienna 10
Charlotte 9
Guangzhou 9
Hefei 9
Norwalk 9
Parma 9
Washington 9
Curitiba 8
Genoa 8
Lappeenranta 8
Ancona 7
Baghdad 7
Johannesburg 7
Kunming 7
Manchester 7
Redwood City 7
Shenzhen 7
Bay Shore 6
Bogotá 6
Brussels 6
Da Nang 6
Hangzhou 6
Kilburn 6
Marseille 6
Nanchang 6
Philadelphia 6
Pisa 6
Totale 10.845
Salva come PNG Salva come JPEG
Nome #
La mutazione di tipo A della nucleofosmina nella diagnosi e nel follow-up della leucemia mieloide acuta 910
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 474
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 466
Clonal evolution in therapy-related neoplasms 462
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 456
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 454
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 452
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 443
Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells 434
Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress 419
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 405
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 402
Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups (Blood Cancer Journal (2013) 3 (e147) DOI:10.1038/bcj.2013.46) 383
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 368
Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia 343
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy 322
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 315
The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells 305
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 301
Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia 300
Acute promyelocytic Leukemia: Update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies 284
MRD in AML: The Role of New Techniques 259
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 247
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes 235
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia 229
WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine 222
Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells 212
Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML 192
Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia 184
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia 156
Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting 156
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 148
Acute myeloid leukemia with NPM1 mutation and disseminated leukaemia cutis: achievement of molecular complete remission by venetoclax/azacytidine combination in a very old patient 143
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation 142
Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways 141
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients 141
Poly(ADP-Ribose) polymerase inhibitors for arsenic trioxide-resistant acute promyelocytic leukemia: synergistic in vitro antitumor effects with hypomethylating agents or high-dose vitamin C 140
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes 138
An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone 136
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML 135
A complex clinical presentation of ultra-high risk acute promyelocytic leukemia: A case report and insights on management 134
New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia 134
Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia 132
Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment 126
Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient 119
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 119
The Anti-Leukemia Effect of Ascorbic Acid: From the Pro-Oxidant Potential to the Epigenetic Role in Acute Myeloid Leukemia 114
From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression 114
A fatal case of peritonitis due to colonic localization of acute myeloid leukemia 104
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib 100
When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia 98
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia 90
Characterization of a novel IDH2‐R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation 90
Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD–positive acute myeloid leukemia 90
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations 89
Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia 88
Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis 87
Combination treatment of resistant acute promyelocytic leukemia cells with arsenic trioxide and anti-apoptotic gene inhibitors 84
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19 84
Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection 84
YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells 82
The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells 81
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias 81
Targeting lactate metabolism by inhibiting MCT1 or MCT4 impairs leukemic cell proliferation, induces two different related death-pathways and increases chemotherapeutic sensitivity of acute myeloid leukemia cells 80
Case report: very late, atypical extra-medullary relapse in a patient with acute promyelocytic leukemia (APL) rescued with a transplant-free approach 74
Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments 70
Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept 66
STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype 66
Risk-adapted MRD-directed therapy for young acute myeloid leukemia adults: 6-year update of the GIMEMA AML1310 trial 62
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia 61
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis 57
Diagnosis and Classification of AML: WHO 2016 56
IDH1 mutation in acute lymphoblastic leukemia—A rare but significant finding 55
The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis 52
APL‐like subset within NPM1‐mutated AML: A distinct immunophenotype correlating with early vascular complications 41
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia 30
Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia 28
Totale 15.176
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022555 0 30 40 14 17 49 20 44 48 49 49 195
2022/2023975 96 67 59 129 61 174 146 58 91 15 38 41
2023/2024686 92 18 91 42 56 136 50 33 35 26 18 89
2024/20251.783 87 268 143 135 62 157 202 131 187 155 150 106
2025/20263.674 278 159 620 237 388 107 504 345 343 290 221 182
2026/2027362 193 169 0 0 0 0 0 0 0 0 0 0
Totale 15.176